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In their recent meta-analysis, Vlaanderen et al. 
(2011) claimed to show evidence for associa-
tions between occupational benzene exposure 
and risks of multiple myeloma, acute lympho-
cytic leukemia, and chronic lymphocytic leu-
kemia. However, one of the larger available 
studies, including 5,514 benzene-exposed UK 
workers (Sorahan et al. 2005), was excluded 
from this meta-analysis, apparently because 
the study had an elevated standardized mortal-
ity ratio (SMR) for secondary and unspecified 
cancers. On the basis of national mortality 
rates, we would have expected 7% of all can-
cer deaths in the UK study to have been in 
the unspecified cate  gory (e.g., carcinomatosis, 
mesothelioma with site unspecified); however, 
9% of deaths were unspecified. Given the size 
of the study (2,430 deaths from all causes), 
this difference was statistically significant 
(Sorahan et al. 2005). Is it reasonable to con-
clude that a study with 93% of cancer deaths 
with site of cancer specified is informative but 
one with only 91% specified is not? I do not 
believe that it is. Vlaanderen et al. (2011) are 
of course free to come to a different conclu-
sion, but any conclusion they reach must be 
implemented in an even-handed way. Some 
obvious questions then arise: a) How elevated 
did the SMR for unspecified cancers have 
to be for a study to be excluded from their 
meta-analysis? b) Were all the other studies 
assessed against this criterion? c) How many 
studies did not provide enough information 
for this criterion to be assessed? d) Why was 
this number not supplied by Vlaanderen et al. 
(2011)? 
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We appreciate Sorahan’s interest in our study 
(Vlaanderen et al. 2011). We first evaluated 
the article by Sorahan et al. (2005) for inclu-
sion in our meta-analysis based on its analy-
sis of cancer incidence, which is consistent 
with our stated preference for using incidence 
rather than mortality data when both were 
available (Vlaanderen et al. 2011). Because the 
authors themselves had expressed serious con-
cerns with regard to the under  ascertainment 
of cancer registrations (incidence) (Sorahan 
et al. 2005), we decided not to include these 
data and instead considered their mortality 
analysis, which was included in the same arti-
cle (Sorahan et al. 2005). We then decided to 
exclude their mortality data as well because of 
their “inability to identify the type of cancer 
for a number of cancer deaths” (Vlaanderen 
et al. 2011). A total of 9% of all cancer deaths 
were not identified by type by Sorahan et al. 
(2005), compared to 2–6% from the publica-
tions we considered for inclusion that pro-
vided such data (9 of 40 cohorts reviewed). 
We did not make this decision based on the 
SMR for this category, as Sorahan claimed 
in his letter. Inclusion of the mortality data 
from Sorahan et al. (2005) has a negligible 
impact on our results [Table 1 compared with 
Supplemental Material, Table 1 of our paper 
(http://dx.doi.org/10.1289/ehp.1002318)] 
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Table 1. Pooled risk estimates (and 95% confidence intervals) for AML and five lymphoma subtypes stratified by start of 
follow-up and AML significance level and including data from Sorahan et al. (2005).
Lymphoma subtype/
AML significance 
levela
No. of 
studies 
No. of 
cases
Meta relative 
risk (all studies)
No. of 
studies 
No. of 
cases
Meta risk ratio 
(start follow-up 
before 1970)
No. of 
studies 
No. of 
cases
Meta risk ratio 
(start follow-up 
1970 and later)
AML
A–E (all studies) 22 229 1.69 (1.38–2.08)* 13 131 1.47 (1.12–1.92)* 9 98 2.08 (1.59–2.72)
A–D 22 229 1.69 (1.38–2.08)* 13 131 1.47 (1.12–1.92)* 9 98 2.08 (1.59–2.72)
A–C 17 204 1.87 (1.57–2.22) 9 112 1.72 (1.38–2.15) 8 92 2.11 (1.61–2.77)
A–B 12 144 2.15 (1.76–2.63) 6 76 1.99 (1.51–2.60) 6 68 2.41 (1.77–3.29)
A 10 120 2.38 (1.89–2.99) 5 63 2.13 (1.57–2.89) 5 57 2.88 (1.95–3.99) 
HL
A–E (all studies) 28 149 1.00 (0.84–1.18) 20 126 1.01 (0.84–1.23) 8 23 0.91 (0.59–1.40)
A–D 13 72 0.99 (0.78–1.27) 9 61 1.03 (0.79–1.35) 4 11 0.83 (0.47–1.48)
A–C 10 42 0.84 (0.61–1.16) 6 31 0.84 (0.57–1.24) 4 11 0.83 (0.47–1.48)
A–B 6 10 0.57 (0.30–1.10) 3 9 0.65 (0.31–1.38) 3 1b 0.40 (0.11–1.44)
A 5 10 0.61 (0.31–2.19) 3 9 0.65 (0.31–1.38)   2 1c 0.46 (0.10–2.09)
NHLd
A–E (all studies) 34 662 1.00 (0.89–1.12)* 23 467 0.93 (0.82–1.05) 11 195 1.21 (0.94–1.55)*
A–D 16 398 0.96 (0.81–1.14) 9 223 0.83 (0.68–1.01) 7 175 1.18 (0.91–1.53)*
A–C 14 359 0.98 (0.81–1.18) 7 184 0.83 (0.65–1.05) 7 175 1.18 (0.91–1.53)*
A–B 8 145 1.16 (0.85–1.57) 3 55 0.89 (0.62–1.27) 5 90 1.38 (0.92–2.06)*
A 7 116 1.10 (0.78–1.55) 3 55 0.89 (0.62–1.27) 4 61 1.40 (0.79–2.51)*
MM
A–E (all studies) 27 290 1.11 (0.97–1.26) 17 210 1.06 (0.92–1.22) 10 80 1.26 (0.92–1.71) 
A–D 15 166 1.13 (0.93–1.37) 8 111 1.06 (0.87–1.30) 7 55 1.27 (0.81–2.00)*
A–C 13 143 1.15 (0.91–1.44) 6 88 1.08 (0.86–1.34) 7 55 1.27 (0.81–2.00)*
A–B 8 75 1.40 (1.02–1.90) 3 35 1.20 (0.73–2.00)   5 40 1.58 (1.03–2.44) 
A 7 62 1.42 (0.97–2.08) 3 35 1.20 (0.73–2.00)   4 27 1.75 (0.94–3.26)
ALL
A–E (all studies) 18 47 1.41 (1.02–1.97) 11 30 1.27 (0.86–1.87) 7 17 1.92 (1.00–3.67)
A–D 18 47 1.41 (1.02–1.97) 11 30 1.27 (0.86–1.87) 7 17 1.92 (1.00–3.67)
A–C 12 29 1.36 (0.88–2.10) 6 15 1.04 (0.60–1.81) 6 14 2.10 (1.04–4.25)
A–B 8 16 1.59 (0.85–2.99) 3 5 0.98 (0.38–2.58) 5 11 2.28 (0.99–5.26)
A 6 12 1.52 (0.71–3.26) 2 3 0.88 (0.27–2.81)   4 9 2.30 (0.84–6.29)
CLL
A–E (all studies) 19 116 1.16 (0.81–1.65)* 12 74 0.91 (0.56–1.48)* 7 42 1.63 (1.09–2.44)
A–D 19 116 1.16 (0.81–1.65)* 12 74 0.91 (0.56–1.48)   7 42 1.63 (1.09–2.44)
A–C 14 98 1.20 (0.78–1.84)* 8 60 0.91 (0.47–1.75) 6 38 1.61 (1.00–2.59)
A–B 9 62 1.37 (0.80–2.35)* 5 43 1.13 (0.43–2.97)   4 19 1.84 (1.12–3.02)
A 7 50 1.36 (0.74–2.51) 4 41 1.40 (0.49–4.01) 3 9 1.33 (0.64–2.76)
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; HL, 
Hodgkin lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma. Data presented here correspond to Supplemental 
Material, Table 1 from Vlaanderen et al. (2011; http://dx.doi.org/10.1289/ehp.1002318). Sorahan et al. (2005) was categorized as 
follow-up starting before 1970; AML significance level A [relative risk > 1 (p < 0.1)]; exposure assessment quality D (qualitative 
indication that benzene exposure had occurred). No observed cases were reported for ALL by Sorahan et al. We therefore 
calculated continuity-corrected relative risks (observed and expected number of cases + 1) and estimated associated 95% confi-
dence intervals with mid-P exact.  Values that are different from those in the original analyses are in italic type.
aAML significance level categories: A, AML risk estimate > 1 (p < 0.1); B, AML risk estimate > 1 (p < 0.2); C, AML risk estimate > 1 
(p > 0.2); D, AML risk estimate reported; E, AML risk estimate not reported. bTwo of three studies reported null cases (continuity 
correction was applied in the meta-analysis). cOne of two studies reported null cases (continuity correction was applied in the 
meta-analysis). dNHL or lymphosarcoma/reticulosarcoma (preferred NHL if the study reported both). *p < 0.1 for between-study 
heterogeneity. Correspondence
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and does not alter our conclusion that this 
meta-analysis provides support for an associa-
tion between occupational exposure to ben-
zene and increased risk of multiple myeloma, 
acute lymphocytic leukemia, and chronic lym-
phocytic leukemia (Vlaanderen et al. 2011). 
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We wish to compliment and complement 
the editorial by Landrigan et al. (2011) 
who inter alia synthesized the “Asturias 
Declaration” during the “International 
Conference  on  Environmental  and 
Occupational Determinants of Cancer: 
Interventions for Primary Prevention” 
[World Health Organization (WHO) 
2011]. Although the authors list recom-
mendations that are certainly commend-
able, we strongly disagree with the inclusion 
of “probable” in the suggestion that “the 
WHO should develop a global framework 
for control of environmental and occupa-
tional carcinogens that concentrates on the 
exposures identified by IARC [International 
Agency for Research on Cancer] as proven 
or probable causes of human cancer.” 
Indeed, we would strongly suggest the 
need to focus on the causes of human cancer 
that have been identified by IARC as proven, 
but not on “probable” causes [59 agents have 
been classified by IARC as group 2A, i.e., 
probably carcinogenic to humans (IARC 
2011)] to then direct premature prevention 
efforts on the latter. Soberingly, IARC’s dil-
igent evaluation process of what can and 
what cannot cause cancer in humans would 
be blurred when equating group 1 (proven 
carcino  gen) classifications with group 2A 
classifications, as recommended in the 
Asturias Declaration. A group 2A classifi-
cation is not necessarily part of a one-way 
street to a group 1 verdict.
To provide a recent, empirical example, 
shift-work that involves circadian disruption 
was classified as a probable human carcinogen 
(Straif et al. 2007). Importantly, though, as 
long as causality is not established, we should 
clearly be deterred from activities that are not 
driven by data. Moreover, means for primary 
prevention are elusive (Erren et al. 2009): 
Shift-work is unavoidable in our 24/7 societ-
ies, and it is impossible with today’s state of 
knowledge to identify workers who are robust 
to shift-work conditions and to dissuade oth-
ers who may be susceptible to the effects of 
circadian disruption  or chrono  disruption 
(Erren et al. 2008; Erren and Reiter 2008). 
An IARC classification of “probable” human 
carcino  gen, which implies uncertainty and 
the possibility that future research may exon-
erate the “culprit in question,” is certainly not 
an appropriate yardstick to guide valuable 
and limited resources. Instead, we should 
invest in controlling established carcino  gens 
such as asbestos and smoking. 
Overall, when Richard Nixon declared 
the war on cancer on 23 December 1971, 
he remarked, “I hope in the years ahead 
that we may look back on this day and this 
action as being the most significant action 
taken during this administration” (Nixon 
1971b). That initiative certainly is not—not 
only because of the Watergate scandal but, 
importantly, because of the highly ambi-
tious goal “to find a cure for cancer” (Nixon 
1971a). Lacking insights into how to cure 
cancer in the majority of cases, our objective 
for now—and presumably for many years to 
come—should be improved primary preven-
tion of environmentally and occupationally 
caused cancers. Clearly, although progress 
in prevention is necessary and feasible, it is 
imperative to identify realistic and defensible 
goals and strategies. To this end, a sensible 
recom  mendation for strategy would be that 
“a new global policy framework for envi-
ronmental cancer” (Landrigan et al. 2011) 
should focus on established carcinogens 
such as asbestos, “smoking, overweight, and 
inactivity” (Willett et al. 2011)—but not on 
probable culprits. 
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We thank Erren et al. for their positive 
comments about our editorial on environ-
mental and occupational causes of cancer 
(Landrigan et al. 2011). In particular, we 
acknowledge their support of our central the-
sis, expressed in the Declaration of Asturias 
[World Health Organization (WHO) 2011], 
that control of the toxic chemical causes of 
cancer must be a core component of global 
cancer control programs, equal in impor-
tance with efforts to understand and control 